{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:32:39Z","timestamp":1792373559093,"version":"4.4.0"},"reference-count":218,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/21645515.2025.2469416","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:46:24Z","timestamp":1742939184000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy"],"prefix":"10.1080","volume":"21","author":[{"given":"Chinmay T.","family":"Jani","sequence":"first","affiliation":[{"name":"University of Miami Leonard M. Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysswarya","family":"Manoharan","sequence":"additional","affiliation":[{"name":"University of Miami Leonard M. Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"DeMaria","sequence":"additional","affiliation":[{"name":"NEXT Oncology","place":["San Antonio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijo","family":"Bilusic","sequence":"additional","affiliation":[{"name":"University of Miami Leonard M. Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000640"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.12.001"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3387-7_43"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/07859264"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines0615"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s3045-022-01247-x"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1586\/10584.2013.86914"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.67932"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-3"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/postgradmedj\/79.938.672"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a1646"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1936.tb5958.x"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.09.053"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2017.126"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.2169\/naika.78.500"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01274-08"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2014.00051"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.10115"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3869"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.145.11.3540"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines0048"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2121"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.04.004"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s0588-019-00133-4"},{"key":"e_1_3_6_28_1","unstructured":"ClinicalTrials.gov. A phase 1 safety and tolerability study of personalized live attenuated double-deleted listeria monocytogenes (pLADD) immunotherapy in adults with metastatic colorectal cancer. ClinicalTrials.Gov identifier: NCT9030. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT9030."},{"key":"e_1_3_6_29_1","unstructured":"ClinicalTrials.gov. Epacadostat pembrolizumab and CRS-207 with or without CY\/GVAX pancreas in patients with metastatic pancreas cancer. ClinicalTrials.Gov identifier: NCT6302. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT6302."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00274-08"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac048"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/25515.2021.13036"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0088"},{"key":"e_1_3_6_34_1","unstructured":"ClinicalTrials.gov. A study of the clinical activity and safety of JNJ-61809 a live attenuated listeria monocytogenes immunotherapy in combination with apalutamide versus apalutamide in subjects with metastatic castration-resistant prostate cancer. ClinicalTrials.Gov identifier: NCT6605. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT6605."},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.10103"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s1391-021-00402-8"},{"key":"e_1_3_6_37_1","unstructured":"ClinicalTrials.gov. RT201 (tumor antigen-specific macrophage tumor vaccine). ClinicalTrials.Gov identifier: NCT0301. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0301."},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.18011"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1276"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1350"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00144-19"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-512-1_16"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.23007"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2013.86"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7038"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms1630"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.23285"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.142"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/02371-23000-00011"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/22402X.2017.13584"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000325"},{"key":"e_1_3_6_52_1","unstructured":"ClinicalTrials.gov. Saltikva for metastatic pancreatic cancer. NCT9234. Sponsor: Salispera LLC. [Active not recruiting] [accessed 2024 Apr 24]. https:\/\/clinicaltrials.gov\/."},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-08238"},{"key":"e_1_3_6_54_1","unstructured":"ClinicalTrials.gov. Study of SGN1 administered via intratumoral injection in patients with advanced solid tumor. ClinicalTrials.Gov identifier: NCT3345. https:\/\/clinicaltrials.gov\/study\/NCT3345."},{"key":"e_1_3_6_55_1","unstructured":"ClinicalTrials.gov. Study of SGN1 in patients with advanced solid tumor. ClinicalTrials.Gov identifier: NCT8150. https:\/\/clinicaltrials.gov\/study\/NCT8150."},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/12598.2021.18672"},{"key":"e_1_3_6_57_1","unstructured":"ClinicalTrials.gov. Multiple myeloma trial of orally administered salmonella based survivin vaccine (MAPSS). ClinicalTrials.Gov identifier: NCT2291. https:\/\/www.clinicaltrials.gov\/study\/NCT2291."},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.1117"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl8295"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3073"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s1585-018-0055-4"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2015.05.005"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.00693"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e1574"},{"key":"e_1_3_6_67_1","unstructured":"ClinicalTrials.gov. Different strains of BCG with or without vaccine in high grade non-muscle invasive bladder cancer. (S1602). ClinicalTrials.Gov identifier: NCT1660. https:\/\/www.clinicaltrials.gov\/study\/NCT1660."},{"key":"e_1_3_6_68_1","unstructured":"ClinicalTrials.gov. Multicenter clinical trial on the effectiveness and safety of instillation of BCG and Alternative BCG protocols for intermediate and high-risk non-muscle invasive bladder cancer. ClinicalTrials.Gov identifier: NCT1110. https:\/\/www.clinicaltrials.gov\/study\/NCT1110."},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1586\/10584.1.4.495"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1698"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.1790"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.34172\/bi.2021.25"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009623664253"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/1423-0127-17-21"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000337"},{"issue":"10","key":"e_1_3_6_76_1","first-page":"3012","article-title":"Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes","volume":"7","author":"Slingluff CL","year":"2001","unstructured":"Slingluff CL Jr., Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7(10):3012\u20133024.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-2336"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0276"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/femsyr\/foz007"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines0479"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0396.2006.00663.x"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1567-1364.2010.00665.x"},{"issue":"3","key":"e_1_3_6_83_1","first-page":"895","article-title":"Yeast-based identification of prostate tumor antigens provides an effective vaccine platform","volume":"30","author":"Jung V","year":"2010","unstructured":"Jung V, Fischer E, Imig J, Kleber S, Nuber N, Reinshagen F, Kamradt J, Grobholz R, Knuth A, Renner C, et al. Yeast-based identification of prostate tumor antigens provides an effective vaccine platform. Anticancer Res. 2010;30(3):895\u2013902.","journal-title":"Anticancer Res"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.28"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1295"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0393"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.11.033"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s0262-013-1505-8"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2014.06.002"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1089\/pancan.2020.0021"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.13688"},{"key":"e_1_3_6_92_1","unstructured":"ClinicalTrials.gov. Cancer vaccine targeting brachyury protein in tumors. ClinicalTrials.Gov identifier: NCT9817. https:\/\/clinicaltrials.gov\/study\/NCT9817."},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0119"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13720"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-03238"},{"key":"e_1_3_6_96_1","unstructured":"ClinicalTrials.gov. QUILT-3.080: NANT pancreatic cancer vaccine. ClinicalTrials.Gov identifier: NCT6869. https:\/\/www.clinicaltrials.gov\/study\/NCT6869."},{"key":"e_1_3_6_97_1","unstructured":"ClinicalTrials.gov. QUILT-3.060: NANT pancreatic cancer vaccine: molecularly informed integrated immunotherapy in subjects with pancreatic cancer who have progressed on or after standard-of-care therapy. ClinicalTrials.Gov identifier: NCT9248. https:\/\/www.clinicaltrials.gov\/study\/NCT9248."},{"key":"e_1_3_6_98_1","unstructured":"ClinicalTrials.gov. QUILT 3.071: NANT colorectal cancer (CRC) vaccine. ClinicalTrials.Gov identifier: NCT3157. https:\/\/www.clinicaltrials.gov\/study\/NCT3157."},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e2566"},{"key":"e_1_3_6_100_1","unstructured":"ClinicalTrials.gov. QUILT-3.067: NANT triple negative breast cancer (TNBC) vaccine: molecularly informed integrated immunotherapy in subjects with TNBC who have progressed on or after standard-of-care therapy. ClinicalTrials.Gov identifier: NCT7085. https:\/\/www.clinicaltrials.gov\/study\/NCT7085."},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.60108"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e2325e63"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.71015"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.93410"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1080\/22402X.2015.15641"},{"key":"e_1_3_6_106_1","unstructured":"ClinicalTrials.gov. Oncolytic virus studies. [accessed 2024 Sep 15]. https:\/\/www.clinicaltrials.gov\/search?term=oncolytic%20virus&aggFilters=status:act%20not%20rec."},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.2527"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.19.8802"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)90341-7"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2006.05.005"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2022-0002"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI2672"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01190-07"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1995.1130"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.11.022"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0073"},{"issue":"22","key":"e_1_3_6_117_1","first-page":"5800","article-title":"A triad of costimulatory molecules synergize to amplify T-cell activation","volume":"59","author":"Hodge JW","year":"1999","unstructured":"Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999;59(22):5800\u20135807.","journal-title":"Cancer Res"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0156"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1087"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5048"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.243"},{"key":"e_1_3_6_122_1","unstructured":"ClinicalTrials.gov. Hepatocellular carcinoma study comparing vaccinia virus based immunotherapy plus sorafenib vs sorafenib alone (PHOCUS). ClinicalTrials.Gov identifier: NCT2755. https:\/\/www.clinicaltrials.gov\/study\/NCT2755."},{"key":"e_1_3_6_123_1","unstructured":"ClinicalTrials.gov. A study of recombinant vaccinia virus in combination with cemiplimab for renal cell carcinoma. ClinicalTrials.Gov identifier: NCT4083. https:\/\/www.clinicaltrials.gov\/study\/NCT4083."},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.194"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.101"},{"key":"e_1_3_6_126_1","unstructured":"ClinicalTrials.gov. Safety of recombinant human IL-21 oncolytic vaccinia virus Injection\uff08hV01) in advanced tumors. ClinicalTrials.Gov identifier: NCT4376. https:\/\/www.clinicaltrials.gov\/study\/NCT4376."},{"key":"e_1_3_6_127_1","unstructured":"ClinicalTrials.gov. A clinical study on evaluating intravenous administration of IDOV-SAFE. ClinicalTrials.Gov identifier: NCT0309. https:\/\/www.clinicaltrials.gov\/study\/NCT0309."},{"key":"e_1_3_6_128_1","unstructured":"ClinicalTrials.gov. A phase I clinical study of intratumoral injection oncolytic vaccinia virus GC001 in patient with advanced solid tumors. ClinicalTrials.Gov identifier: NCT8307. https:\/\/www.clinicaltrials.gov\/study\/NCT8307."},{"key":"e_1_3_6_129_1","unstructured":"ClinicalTrials.gov. A clinical trial of TG6050 in patients with metastatic non-small cell lung cancer (Delivir). ClinicalTrials.Gov identifier: NCT8926. https:\/\/www.clinicaltrials.gov\/study\/NCT8926."},{"key":"e_1_3_6_130_1","unstructured":"ClinicalTrials.gov. Exploratory study of a novel oncolytic vaccinia virus RGV004 in the treatment of refractory\/relapsed B-cell lymphoma. ClinicalTrials.Gov identifier: NCT7025. https:\/\/www.clinicaltrials.gov\/study\/NCT7025."},{"key":"e_1_3_6_131_1","unstructured":"ClinicalTrials.gov. Safety and efficacy of KM1 in subjects with recurrent or refractory ovarian cancer (K9017-004). ClinicalTrials.Gov identifier: NCT4731. https:\/\/www.clinicaltrials.gov\/study\/NCT4731."},{"key":"e_1_3_6_132_1","unstructured":"ClinicalTrials.gov. Efficacy & safety of olvimulogene nanivacirepvec & platinum-doublet + physician\u2019s choice of immune checkpoint inhibitor compared to docetaxel in NSCL cancer (VIRO-25). ClinicalTrials.Gov identifier: NCT3665. https:\/\/www.clinicaltrials.gov\/study\/NCT3665."},{"key":"e_1_3_6_133_1","unstructured":"ClinicalTrials.gov. Efficacy & safety of olvi-vec and platinum-doublet + bevacizumab compared to physician\u2019s choice of chemotherapy and bevacizumab in platinum-resistant\/refractory ovarian cancer (PRROC) (OnPrime GOG-3076). ClinicalTrials.Gov identifier: NCT1471. https:\/\/www.clinicaltrials.gov\/study\/NCT1471."},{"key":"e_1_3_6_134_1","unstructured":"ClinicalTrials.gov. A study of VET3-TGI in patients with solid tumors (STEALTH-001). ClinicalTrials.Gov identifier: NCT4815. https:\/\/www.clinicaltrials.gov\/study\/NCT4815."},{"key":"e_1_3_6_135_1","unstructured":"ClinicalTrials.gov. A clinical trial assessing BT-001 alone and in combination with pembrolizumab in metastatic or advanced solid tumors. ClinicalTrials.Gov identifier: NCT5331. https:\/\/www.clinicaltrials.gov\/study\/NCT5331."},{"key":"e_1_3_6_136_1","doi-asserted-by":"publisher","DOI":"10.4110\/in.2021.21.e6"},{"key":"e_1_3_6_137_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566523213665046"},{"key":"e_1_3_6_138_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers1295"},{"key":"e_1_3_6_139_1","doi-asserted-by":"publisher","DOI":"10.1007\/s0262-015-1706-4"},{"key":"e_1_3_6_140_1","doi-asserted-by":"publisher","DOI":"10.1007\/s0262-013-1400-3"},{"key":"e_1_3_6_141_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab046"},{"key":"e_1_3_6_142_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5181"},{"key":"e_1_3_6_143_1","unstructured":"ClinicalTrials.gov. Testing a combination of vaccines for cancer prevention in lynch syndrome. ClinicalTrials.Gov identifier: NCT9011. https:\/\/www.clinicaltrials.gov\/study\/NCT9011."},{"key":"e_1_3_6_144_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.11.59"},{"key":"e_1_3_6_145_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2006.17.220"},{"key":"e_1_3_6_146_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-02374"},{"key":"e_1_3_6_147_1","unstructured":"ClinicalTrials.gov. MG1 Maraba\/MAGE-A3 with and without adenovirus vaccine with transgenic MAGE-A3 insertion in incurable MAGE-A3-Expressing solid tumours. ClinicalTrials.Gov identifier: NCT5816. https:\/\/www.clinicaltrials.gov\/study\/NCT5816."},{"key":"e_1_3_6_148_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e4637"},{"key":"e_1_3_6_149_1","unstructured":"ClinicalTrials.gov. Oncolytic MG1-MAGEA3 with ad-MAGEA3 vaccine in combination with pembrolizumab for non-small cell lung cancer patients. ClinicalTrials.Gov identifier: NCT9760. https:\/\/www.clinicaltrials.gov\/study\/NCT9760."},{"key":"e_1_3_6_150_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.11912"},{"key":"e_1_3_6_151_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2628"},{"key":"e_1_3_6_152_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5623"},{"key":"e_1_3_6_153_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1072"},{"key":"e_1_3_6_154_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines0325"},{"key":"e_1_3_6_155_1","unstructured":"ClinicalTrials.gov. Nous-209 genetic vaccine for the treatment of microsatellite unstable solid tumors. ClinicalTrials.Gov identifier: NCT1310. https:\/\/www.clinicaltrials.gov\/study\/NCT1310."},{"key":"e_1_3_6_156_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-ITOC.444"},{"key":"e_1_3_6_157_1","unstructured":"ClinicalTrials.gov. Cancer preventive vaccine nous-209 for lynch syndrome patients. ClinicalTrials.Gov identifier: NCT8866. https:\/\/www.clinicaltrials.gov\/study\/NCT8866."},{"key":"e_1_3_6_158_1","unstructured":"ClinicalTrials.gov. A vaccine trial for patients with stage IIIB IV or recurrent non-small cell lung cancer (VTNSCLC). ClinicalTrials.Gov identifier: NCT4222. https:\/\/www.clinicaltrials.gov\/study\/NCT4222."},{"key":"e_1_3_6_159_1","unstructured":"ClinicalTrials.gov. Vaccine therapy in treating patients with stage IIIB stage IV or recurrent non-small cell lung cancer. ClinicalTrials.Gov identifier: NCT1094. https:\/\/www.clinicaltrials.gov\/study\/NCT1094."},{"key":"e_1_3_6_160_1","unstructured":"ClinicalTrials.gov. CCL21-gene modified dendritic cell vaccine and pembrolizumab in treating patients with stage IV non-small cell lung cancer. ClinicalTrials.Gov identifier: NCT6361. https:\/\/www.clinicaltrials.gov\/study\/NCT6361."},{"key":"e_1_3_6_161_1","unstructured":"ClinicalTrials.gov. DCs vaccine combined with cytokine-induced killer cells in patients with AML. ClinicalTrials.Gov identifier: NCT8663. https:\/\/www.clinicaltrials.gov\/study\/NCT8663."},{"key":"e_1_3_6_162_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-6-59"},{"key":"e_1_3_6_163_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.509"},{"key":"e_1_3_6_164_1","unstructured":"ClinicalTrials.gov. Trial investigating an immunostimulatory oncolytic adenovirus for cancer. ClinicalTrials.Gov identifier: NCT5989. https:\/\/www.clinicaltrials.gov\/study\/NCT5989.a"},{"key":"e_1_3_6_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00079-2"},{"issue":"7","key":"e_1_3_6_166_1","first-page":"Abstract nr 666","article-title":"Immunostimulatory gene therapy targeting CD40\/4-1BB in combination with chemotherapy induces an inflammatory gene profile in tumors from patients with advanced disease [abstract]. In: proceedings of the American association for cancer research annual meeting 2023; part 1 (regular and invited abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR","volume":"83","author":"Wenthe J","year":"2023","unstructured":"Wenthe J, Eriksson E, Naseri S, Sandin L, Hahn A, Irenaeus S, Sundin A, Leja-Jarblad J, Ullenhag G, L\u00f6vgren T, et al. Immunostimulatory gene therapy targeting CD40\/4-1BB in combination with chemotherapy induces an inflammatory gene profile in tumors from patients with advanced disease [abstract]. In: proceedings of the American association for cancer research annual meeting 2023; part 1 (regular and invited abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR. Cancer Res. 2023;83(7_Suppl):Abstract nr 6663.","journal-title":"Cancer Res"},{"key":"e_1_3_6_167_1","unstructured":"ClinicalTrials.gov. LOAd703 oncolytic virus therapy for pancreatic cancer. ClinicalTrials.Gov identifier: NCT5196. https:\/\/www.clinicaltrials.gov\/study\/NCT5196."},{"key":"e_1_3_6_168_1","unstructured":"ClinicalTrials.gov. H101 recombinant human adenovirus type 5 plus HAIC of FOLFOX for intrahepatic cholangiocarcinoma. ClinicalTrials.Gov identifier: NCT4002. https:\/\/www.clinicaltrials.gov\/study\/NCT4002."},{"key":"e_1_3_6_169_1","unstructured":"ClinicalTrials.gov. H101 oncolytic Adenovirus(H101) combined with PD-1 inhibitors in patients with advanced malignant pleural mesothelioma. ClinicalTrials.Gov identifier: NCT1636. https:\/\/www.clinicaltrials.gov\/study\/NCT1636."},{"key":"e_1_3_6_170_1","unstructured":"ClinicalTrials.gov. H101 combined with camrelizumab for recurrent cervical cancer. ClinicalTrials.Gov identifier: NCT4905. https:\/\/www.clinicaltrials.gov\/study\/NCT4905."},{"key":"e_1_3_6_171_1","unstructured":"ClinicalTrials.gov. Oncolytic adenovirus TILT-123 and avelumab for treatment of solid tumors refractory to or progressing after anti-PD(L)1. AVENTIL. ClinicalTrials.Gov identifier: NCT2932. https:\/\/www.clinicaltrials.gov\/study\/NCT2932."},{"key":"e_1_3_6_172_1","unstructured":"ClinicalTrials.gov. Oncolytic adenovirus coding for TNFa and IL2 (TILT-123) with pembrolizumab or pembrolizumab and pegylated liposomal doxorubicin as treatment for ovarian cancer. (PROTA). ClinicalTrials.Gov identifier: NCT1318. https:\/\/www.clinicaltrials.gov\/study\/NCT1318."},{"key":"e_1_3_6_173_1","unstructured":"ClinicalTrials.gov. TNF\u03b1 and IL-2 coding oncolytic adenovirus TILT-123 monotherapy (TUNIMO). ClinicalTrials.Gov identifier: NCT5327. https:\/\/www.clinicaltrials.gov\/study\/NCT5327."},{"key":"e_1_3_6_174_1","unstructured":"ClinicalTrials.gov. TNFalpha and interleukin 2 coding oncolytic adenovirus TILT-123 during TIL treatment of advanced melanoma (TUNINTIL). ClinicalTrials.Gov identifier: NCT7473. https:\/\/www.clinicaltrials.gov\/study\/NCT7473."},{"key":"e_1_3_6_175_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3874"},{"key":"e_1_3_6_176_1","doi-asserted-by":"publisher","DOI":"10.1186\/s3046-024-03219-0"},{"key":"e_1_3_6_177_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03324-9"},{"key":"e_1_3_6_178_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm198"},{"key":"e_1_3_6_179_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1706"},{"key":"e_1_3_6_180_1","unstructured":"ClinicalTrials.gov. First in man clinical study to evaluate safety and tolerability of an oncolytic adenovirus in prostate cancer patients. ClinicalTrials.Gov identifier: NCT7002. https:\/\/www.clinicaltrials.gov\/study\/NCT7002."},{"key":"e_1_3_6_181_1","unstructured":"ClinicalTrials.gov. MSC-DNX-2401 in treating patients with recurrent high-grade glioma. ClinicalTrials.Gov identifier: NCT6568. https:\/\/www.clinicaltrials.gov\/study\/NCT6568."},{"key":"e_1_3_6_182_1","unstructured":"ClinicalTrials.gov. MEM-288 oncolytic virus alone and in combination with nivolumab in solid tumors including non-small cell lung cancer. ClinicalTrials.Gov identifier: NCT6760. https:\/\/www.clinicaltrials.gov\/study\/NCT6760."},{"key":"e_1_3_6_183_1","unstructured":"ClinicalTrials.gov. Ixovex-1 single agent and combination therapy (IXACT). ClinicalTrials.Gov identifier: NCT9946. https:\/\/www.clinicaltrials.gov\/study\/NCT9946."},{"key":"e_1_3_6_184_1","unstructured":"ClinicalTrials.gov. Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST advanced HER2 positive solid tumors (VISTA). ClinicalTrials.Gov identifier: NCT0256. https:\/\/www.clinicaltrials.gov\/study\/NCT0256."},{"key":"e_1_3_6_185_1","unstructured":"ClinicalTrials.gov. A clinical study of BioTTT001 in combination with SOX and toripalimab in patients with gastric cancer. ClinicalTrials.Gov identifier: NCT3121. https:\/\/www.clinicaltrials.gov\/study\/NCT3121."},{"key":"e_1_3_6_186_1","unstructured":"ClinicalTrials.gov. A clinical study evaluating the safety and efficacy of BioTTT001 in patients with malignant solid tumors. ClinicalTrials.Gov identifier: NCT5846. https:\/\/www.clinicaltrials.gov\/study\/NCT5846."},{"key":"e_1_3_6_187_1","unstructured":"ClinicalTrials.gov. A clinical study of BioTTT001 in combination with toripalimab and regorafenib in patients with colorectal cancer. ClinicalTrials.Gov identifier: NCT3134. https:\/\/www.clinicaltrials.gov\/study\/NCT3134."},{"key":"e_1_3_6_188_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.1.119"},{"key":"e_1_3_6_189_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.1.16"},{"key":"e_1_3_6_190_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00270"},{"key":"e_1_3_6_191_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.14.5.332"},{"key":"e_1_3_6_192_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers1383"},{"key":"e_1_3_6_193_1","unstructured":"ClinicalTrials.gov. Talimogene Laherparepvec in combination with neoadjuvant chemotherapy in triple negative breast cancer. ClinicalTrials.Gov identifier: NCT9855. https:\/\/www.clinicaltrials.gov\/study\/NCT9855."},{"key":"e_1_3_6_194_1","unstructured":"CAN-3110 receives FDA fast track designation for treatment of recurrent high-grade glioma. News release. Candel therapeutics. 2024 Feb 13 [accessed 2024 Sep 15]. https:\/\/ir.candeltx.com\/news-releases\/news-release-details\/can-3110-receives-fda-fast-track-designation-treatment-recurrent."},{"key":"e_1_3_6_195_1","doi-asserted-by":"publisher","DOI":"10.1038\/s1586-023-06623-2"},{"key":"e_1_3_6_196_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2017.10.005"},{"key":"e_1_3_6_197_1","unstructured":"ClinicalTrials.gov. HSV G207 in children with recurrent or refractory cerebellar brain tumors. ClinicalTrials.Gov identifier: NCT1388. https:\/\/www.clinicaltrials.gov\/study\/NCT1388."},{"key":"e_1_3_6_198_1","unstructured":"ClinicalTrials.gov. Trial of C134 in patients with recurrent GBM (C134-HSV-1). ClinicalTrials.Gov identifier: NCT7576. https:\/\/www.clinicaltrials.gov\/study\/NCT7576."},{"key":"e_1_3_6_199_1","unstructured":"ClinicalTrials.gov. Genetically engineered HSV-1 phase 1 study for the treatment of recurrent malignant glioma (M032-HSV-1). ClinicalTrials.Gov identifier: NCT2827. https:\/\/www.clinicaltrials.gov\/study\/NCT2827."},{"key":"e_1_3_6_200_1","unstructured":"ClinicalTrials.gov. Study of Pembrolizumab and M032 (NSC 73972). ClinicalTrials.Gov identifier: nCT4430. https:\/\/clinicaltrials.gov\/study\/NCT4430."},{"key":"e_1_3_6_201_1","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2016.031"},{"key":"e_1_3_6_202_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms8310"},{"key":"e_1_3_6_203_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2015.10"},{"key":"e_1_3_6_204_1","unstructured":"ClinicalTrials.gov. A phase 1B\/2 study of RP1 in solid organ transplant patients with advanced cutaneous malignancies (ARTACUS). ClinicalTrials.Gov identifier: NCT9436. https:\/\/www.clinicaltrials.gov\/study\/NCT9436."},{"key":"e_1_3_6_205_1","unstructured":"ClinicalTrials.gov. Study evaluating cemiplimab alone and combined with RP1 in treating advanced squamous skin cancer (CERPASS). ClinicalTrials.Gov identifier: NCT0436. https:\/\/www.clinicaltrials.gov\/study\/NCT0436."},{"key":"e_1_3_6_206_1","unstructured":"ClinicalTrials.gov. A randomized phase 2\/3 study to investigate the efficacy and safety of RP2 in combination with nivolumab in immune checkpoint inhibitor-na\u00efve adult patients with metastatic uveal melanoma (RP2-202). ClinicalTrials.Gov identifier: NCT1406. https:\/\/www.clinicaltrials.gov\/study\/NCT1406."},{"key":"e_1_3_6_207_1","unstructured":"ClinicalTrials.gov. RP2\/RP3 in combination with atezolizumab and Bevacizumab for the treatment of patients with CRC. ClinicalTrials.Gov identifier: NCT3611. https:\/\/www.clinicaltrials.gov\/study\/NCT3611."},{"key":"e_1_3_6_208_1","unstructured":"ClinicalTrials.gov. A clinical study on oncolytic virus injection (R130) for the treatment of advanced solid tumors. ClinicalTrials.Gov identifier: NCT0374. https:\/\/www.clinicaltrials.gov\/study\/NCT0374."},{"key":"e_1_3_6_209_1","unstructured":"ClinicalTrials.gov. A clinical study on oncolytic virus injection (R130) for the treatment of relapsed\/refractory advanced solid tumors. ClinicalTrials.Gov identifier: NCT6075. https:\/\/www.clinicaltrials.gov\/study\/NCT6075."},{"key":"e_1_3_6_210_1","unstructured":"ClinicalTrials.gov. A clinical study on oncolytic virus injection (R130) for the treatment of relapsed\/refractory cervical and endometrial cancer. ClinicalTrials.Gov identifier: NCT2677. https:\/\/www.clinicaltrials.gov\/study\/NCT2677."},{"key":"e_1_3_6_211_1","unstructured":"ClinicalTrials.gov. First-in-human (FIH) phase I trial of BS-006 in cervical cancer (CC-OV01). ClinicalTrials.Gov identifier: NCT3440. https:\/\/www.clinicaltrials.gov\/study\/NCT3440."},{"key":"e_1_3_6_212_1","unstructured":"ClinicalTrials.gov. OH2 oncolytic viral therapy in solid tumors. ClinicalTrials.Gov identifier: NCT6525. https:\/\/www.clinicaltrials.gov\/study\/NCT6525."},{"key":"e_1_3_6_213_1","unstructured":"ClinicalTrials.gov. OH2 oncolytic viral therapy in advanced bladder cancer. ClinicalTrials.Gov identifier: NCT8789. https:\/\/www.clinicaltrials.gov\/study\/NCT8789."},{"key":"e_1_3_6_214_1","unstructured":"ClinicalTrials.gov. OH2 OH2 oncolytic viral therapy in non-muscle-invasive bladder cancer. ClinicalTrials.Gov identifier: NCT2136. https:\/\/www.clinicaltrials.gov\/study\/NCT2136."},{"key":"e_1_3_6_215_1","unstructured":"ClinicalTrials.gov. OH2 injection in solid tumors. ClinicalTrials.Gov identifier: NCT6967. https:\/\/www.clinicaltrials.gov\/study\/NCT6967."},{"key":"e_1_3_6_216_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-02224"},{"key":"e_1_3_6_217_1","unstructured":"ClinicalTrials.gov. A clinical study of T3011 in combination with toripalimab and regorafenib in patients with colorectal cancer. ClinicalTrials.Gov identifier: NCT3303. https:\/\/www.clinicaltrials.gov\/study\/NCT3303."},{"key":"e_1_3_6_218_1","unstructured":"ClinicalTrials.gov. A study of T3011 administered via intravenously in patients with advanced solid tumors. ClinicalTrials.Gov identifier: NCT8268. https:\/\/www.clinicaltrials.gov\/study\/NCT8268."},{"key":"e_1_3_6_219_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2520"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2025.2469416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21645515.2025.2469416","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2025.2469416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:31:46Z","timestamp":1786033906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2025.2469416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":218,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/21645515.2025.2469416"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2025.2469416","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2469416"}}